Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom's Macroglobulinemia

Explore clinical trials studying Waldenstrom's Macroglobulinemia. Study availability and eligibility vary by location and protocol.

30 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom's Macroglobulinemia trial results

Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General Hospital Cancer Center Boston, Massachusetts, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01647971

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations
  • TG Therapeutics Investigational Trial Site Huntsville, Alabama, United States
  • TG Therapeutics Investigational Trial Site Jonesboro, Arkansas, United States
  • TG Therapeutics Investigational Trial Site Athens, Georgia, United States
  • TG Therapeutics Investigational Trial Site Macon, Georgia, United States
View Trial Details
Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

NCT02371148

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • AO Riuniti Papardo Piemonte Messina, ME, Italy
  • Centro di Riferimento Oncologico della Basilicata Rionero in Vulture, PZ, Italy
  • AUSL di Ravenna Ravenna, RA, Italy
  • A.O. Bianchi - Melacrino - Morelli Reggio Calabria, RC, Italy
View all 23 locations
View Trial Details
Completed

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Boston, Massachusetts, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. La Roche-sur-Yon, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nantes, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nîmes, France
View Trial Details
Completed

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

NCT01614821

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
Locations
  • Stanford University Palo Alto, California, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
View Trial Details

Related conditions